{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:17:03Z","timestamp":1791897423074,"version":"4.3.4"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Post-Doctor Research Project of Sichuan University","award":["2020HXBH157"],"award-info":[{"award-number":["2020HXBH157"]}]},{"name":"Foundation of Science and Technology Department of Sichuan province","award":["2019YFS0398"],"award-info":[{"award-number":["2019YFS0398"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Comprehensive investigations on the incidence and prognosis of pituitary tumors are still lacking. The present study aims to summarize the incidence, demographics, and survival outcome of pituitary adenoma on a population-based level. This study includes all pituitary adenomas reported in the Surveillance, Epidemiology, and End Results (SEER) database from 2004 to 2016 in the United States. Extensive clinical and demographic characteristics were extracted and submitted to group comparisons. The standardized incidence rate was calculated and stratified by year at diagnosis, age\/sex and age\/treatment groups. The Kaplan\u2013Meier analysis and multivariable regressions were performed to identify the factors associated with overall survival. A total of 47,180 pituitary tumors were identified, including 47,030 typical adenomas, 111 uncertain behavior pituitary adenomas, and 39 pituitary carcinomas. The overall standardized incidence rate was 4.8 cases per 100,000 person-years and the annual incidence rate continually trended upwards, with a peak seen in 2015. We noticed a bimodal age-related distribution in females and a unimodal distribution in males. In the multivariate regression analysis, the factors associated with prolonged survival included typical adenoma, younger age, and smaller tumor size. Whereas, black and male patients had worse overall survival. Our study provides a reliable estimate on the incidence of pituitary adenoma and confirms that the annual standardized incidence rate is increasing. Pituitary adenomas have a satisfactory long-term prognosis and age, tumor size, and tumor subtypes are related to overall survival. Though statistically significant, our inferential findings should be constrained within the limitations of SEER database.<\/jats:p>","DOI":"10.1038\/s41598-021-94658-8","type":"journal-article","created":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T10:11:30Z","timestamp":1627294290000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Incidence, demographics, and survival of patients with primary pituitary tumors: a SEER database study in 2004\u20132016"],"prefix":"10.1038","volume":"11","author":[{"given":"Cheng","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senlin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8017-5833","authenticated-orcid":false,"given":"Peizhi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,26]]},"reference":[{"key":"94658_CR1","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/s41379-018-0016-8","volume":"31","author":"O Mete","year":"2018","unstructured":"Mete, O., Cintosun, A., Pressman, I. & Asa, S. L. Epidemiology and biomarker profile of pituitary adenohypophysial tumors. Mod. Pathol. 31, 900\u2013909. https:\/\/doi.org\/10.1038\/s41379-018-0016-8 (2018).","journal-title":"Mod. Pathol."},{"key":"94658_CR2","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/neuonc\/now130","volume":"19","author":"GU Mehta","year":"2017","unstructured":"Mehta, G. U. & Lonser, R. R. Management of hormone-secreting pituitary adenomas. Neuro Oncol. 19, 762\u2013773. https:\/\/doi.org\/10.1093\/neuonc\/now130 (2017).","journal-title":"Neuro Oncol."},{"key":"94658_CR3","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s11102-011-0308-1","volume":"14","author":"ME Sughrue","year":"2011","unstructured":"Sughrue, M. E., Chang, E. F., Gabriel, R. A., Aghi, M. K. & Blevins, L. S. Excess mortality for patients with residual disease following resection of pituitary adenomas. Pituitary 14, 276\u2013283. https:\/\/doi.org\/10.1007\/s11102-011-0308-1 (2011).","journal-title":"Pituitary"},{"key":"94658_CR4","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1210\/jc.2010-1942","volume":"96","author":"RN Clayton","year":"2011","unstructured":"Clayton, R. N., Raskauskiene, D., Reulen, R. C. & Jones, P. W. Mortality and morbidity in Cushing\u2019s disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J. Clin. Endocrinol. Metab. 96, 632\u2013642. https:\/\/doi.org\/10.1210\/jc.2010-1942 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"94658_CR5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s11102-018-0863-9","volume":"21","author":"M Tampourlou","year":"2018","unstructured":"Tampourlou, M., Fountas, A., Ntali, G. & Karavitaki, N. Mortality in patients with non-functioning pituitary adenoma. Pituitary 21, 203\u2013207. https:\/\/doi.org\/10.1007\/s11102-018-0863-9 (2018).","journal-title":"Pituitary"},{"key":"94658_CR6","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s11102-012-0454-0","volume":"16","author":"M Gruppetta","year":"2013","unstructured":"Gruppetta, M., Mercieca, C. & Vassallo, J. Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary 16, 545\u2013553. https:\/\/doi.org\/10.1007\/s11102-012-0454-0 (2013).","journal-title":"Pituitary"},{"key":"94658_CR7","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1365-2265.2009.03667.x","volume":"72","author":"A Fernandez","year":"2010","unstructured":"Fernandez, A., Karavitaki, N. & Wass, J. A. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin. Endocrinol. (Oxf.) 72, 377\u2013382. https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03667.x (2010).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"94658_CR8","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.1210\/jc.2010-0537","volume":"95","author":"A Raappana","year":"2010","unstructured":"Raappana, A., Koivukangas, J., Ebeling, T. & Pirila, T. Incidence of pituitary adenomas in Northern Finland in 1992\u20132007. J. Clin. Endocrinol. Metab. 95, 4268\u20134275. https:\/\/doi.org\/10.1210\/jc.2010-0537 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"94658_CR9","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1530\/EJE-14-0144","volume":"171","author":"A Tjornstrand","year":"2014","unstructured":"Tjornstrand, A. et al. The incidence rate of pituitary adenomas in western Sweden for the period 2001\u20132011. Eur. J. Endocrinol. 171, 519\u2013526. https:\/\/doi.org\/10.1530\/EJE-14-0144 (2014).","journal-title":"Eur. J. Endocrinol."},{"key":"94658_CR10","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1530\/EJE-15-0189","volume":"173","author":"TT Agustsson","year":"2015","unstructured":"Agustsson, T. T. et al. The epidemiology of pituitary adenomas in Iceland, 1955\u20132012: A nationwide population-based study. Eur. J. Endocrinol. 173, 655\u2013664. https:\/\/doi.org\/10.1530\/EJE-15-0189 (2015).","journal-title":"Eur. J. Endocrinol."},{"key":"94658_CR11","unstructured":"NIH. National Cancer Institute SEER Training Modules. Non-malignant Brain Tumors. https:\/\/training.seer.cancer.gov\/brain\/non-malignant\/. Accessed 10 Nov 2020."},{"key":"94658_CR12","unstructured":"NIH. National Cancer Institute SEER*Stat Databases: November 2019 Submission. https:\/\/seer.cancer.gov\/data-software\/documentation\/seerstat\/nov2019\/. Accessed 15 July 2020."},{"key":"94658_CR13","unstructured":"NIH. National Cancer Institute SEER Incidence Database, How to Request Access to SEER Data. https:\/\/seer.cancer.gov\/data\/access.html. Accessed 15 July 2020."},{"key":"94658_CR14","unstructured":"CS. Collaborative Stage Version 2 Schema List v.02.05.00. IntracranialGland. CS Mets at DX. http:\/\/web2.facs.org\/cstage0205\/intracranialgland\/IntracranialGland_hpa.html. Accessed 21 Nov 2020."},{"key":"94658_CR15","unstructured":"NIH. National Cancer Institute SEER datasets. U.S. Population Data\u20141969\u20132019. https:\/\/seer.cancer.gov\/popdata\/. Accessed 9 Dec 2020."},{"key":"94658_CR16","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1210\/jcem.85.4.6498","volume":"85","author":"B Nilsson","year":"2000","unstructured":"Nilsson, B., Gustavasson-Kadaka, E., Bengtsson, B. A. & Jonsson, B. Pituitary adenomas in Sweden between 1958 and 1991: Incidence, survival, and mortality. J. Clin. Endocrinol. Metab. 85, 1420\u20131425. https:\/\/doi.org\/10.1210\/jcem.85.4.6498 (2000).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"94658_CR17","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1590\/2359-3997000000195","volume":"60","author":"PF Day","year":"2016","unstructured":"Day, P. F. et al. Incidence and prevalence of clinically relevant pituitary adenomas: Retrospective cohort study in a Health Management Organization in Buenos Aires, Argentina. Arch. Endocrinol. Metab. 60, 554\u2013561. https:\/\/doi.org\/10.1590\/2359-3997000000195 (2016).","journal-title":"Arch. Endocrinol. Metab."},{"key":"94658_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11102-010-0253-4","volume":"14","author":"BD McDowell","year":"2011","unstructured":"McDowell, B. D. et al. Demographic differences in incidence for pituitary adenoma. Pituitary 14, 23\u201330. https:\/\/doi.org\/10.1007\/s11102-010-0253-4 (2011).","journal-title":"Pituitary"},{"key":"94658_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2019.101290","volume":"33","author":"P Chanson","year":"2019","unstructured":"Chanson, P. & Maiter, D. The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new. Best Pract. Res. Clin. Endocrinol. Metab. 33, 101290. https:\/\/doi.org\/10.1016\/j.beem.2019.101290 (2019).","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"94658_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000497746","volume":"109","author":"L Vroonen","year":"2019","unstructured":"Vroonen, L., Daly, A. F. & Beckers, A. Epidemiology and management challenges in prolactinomas. Neuroendocrinology 109, 20\u201327. https:\/\/doi.org\/10.1159\/000497746 (2019).","journal-title":"Neuroendocrinology"},{"key":"94658_CR21","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.ecl.2019.05.004","volume":"48","author":"W Huang","year":"2019","unstructured":"Huang, W. & Molitch, M. E. Pituitary tumors in pregnancy. Endocrinol. Metab. Clin. N. Am. 48, 569\u2013581. https:\/\/doi.org\/10.1016\/j.ecl.2019.05.004 (2019).","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"94658_CR22","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.beem.2009.05.003","volume":"23","author":"A Colao","year":"2009","unstructured":"Colao, A. Pituitary tumours: The prolactinoma. Best Pract. Res. Clin. Endocrinol. Metab. 23, 575\u2013596. https:\/\/doi.org\/10.1016\/j.beem.2009.05.003 (2009).","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"94658_CR23","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/eurheartj\/ehs233","volume":"35","author":"R Haring","year":"2014","unstructured":"Haring, R. et al. Positive association of serum prolactin concentrations with all-cause and cardiovascular mortality. Eur. Heart J. 35, 1215\u20131221. https:\/\/doi.org\/10.1093\/eurheartj\/ehs233 (2014).","journal-title":"Eur. Heart J."},{"key":"94658_CR24","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1055\/s-0043-107243","volume":"49","author":"J Krogh","year":"2017","unstructured":"Krogh, J., Selmer, C., Torp-Pedersen, C., Gislason, G. H. & Kistorp, C. Hyperprolactinemia and the association with all-cause mortality and cardiovascular mortality. Horm. Metab. Res. 49, 411\u2013417. https:\/\/doi.org\/10.1055\/s-0043-107243 (2017).","journal-title":"Horm. Metab. Res."},{"key":"94658_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000486000","volume":"49","author":"M Andersen","year":"2018","unstructured":"Andersen, M. & Glintborg, D. Metabolic syndrome in hyperprolactinemia. Front. Horm. Res. 49, 29\u201347. https:\/\/doi.org\/10.1159\/000486000 (2018).","journal-title":"Front. Horm. Res."},{"key":"94658_CR26","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00431-017-3042-5","volume":"177","author":"A Hoffmann","year":"2018","unstructured":"Hoffmann, A., Adelmann, S., Lohle, K., Claviez, A. & Muller, H. L. Pediatric prolactinoma: Initial presentation, treatment, and long-term prognosis. Eur. J. Pediatr. 177, 125\u2013132. https:\/\/doi.org\/10.1007\/s00431-017-3042-5 (2018).","journal-title":"Eur. J. Pediatr."},{"key":"94658_CR27","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1530\/EC-17-0171","volume":"6","author":"E Soto-Pedre","year":"2017","unstructured":"Soto-Pedre, E., Newey, P. J., Bevan, J. S. & Leese, G. P. Morbidity and mortality in patients with hyperprolactinaemia: The PROLEARS study. Endocr. Connect. 6, 580\u2013588. https:\/\/doi.org\/10.1530\/EC-17-0171 (2017).","journal-title":"Endocr. Connect."},{"key":"94658_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/ana.410370113","volume":"37","author":"K Radhakrishnan","year":"1995","unstructured":"Radhakrishnan, K. et al. The trends in incidence of primary brain tumors in the population of Rochester, Minnesota. Ann. Neurol. 37, 67\u201373. https:\/\/doi.org\/10.1002\/ana.410370113 (1995).","journal-title":"Ann. Neurol."},{"key":"94658_CR29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s11102-019-01014-1","volume":"23","author":"V Tardivo","year":"2020","unstructured":"Tardivo, V. et al. Surgical management of pituitary adenomas: Does age matter?. Pituitary 23, 92\u2013102. https:\/\/doi.org\/10.1007\/s11102-019-01014-1 (2020).","journal-title":"Pituitary"},{"key":"94658_CR30","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s11102-017-0839-1","volume":"21","author":"DJ Lobatto","year":"2018","unstructured":"Lobatto, D. J. et al. Preoperative risk factors for postoperative complications in endoscopic pituitary surgery: A systematic review. Pituitary 21, 84\u201397. https:\/\/doi.org\/10.1007\/s11102-017-0839-1 (2018).","journal-title":"Pituitary"},{"key":"94658_CR31","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00401-017-1769-8","volume":"134","author":"MBS Lopes","year":"2017","unstructured":"Lopes, M. B. S. The 2017 World Health Organization classification of tumors of the pituitary gland: A summary. Acta Neuropathol 134, 521\u2013535. https:\/\/doi.org\/10.1007\/s00401-017-1769-8 (2017).","journal-title":"Acta Neuropathol"},{"key":"94658_CR32","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s12022-017-9498-z","volume":"28","author":"O Mete","year":"2017","unstructured":"Mete, O. & Lopes, M. B. Overview of the 2017 WHO classification of pituitary tumors. Endocr. Pathol. 28, 228\u2013243. https:\/\/doi.org\/10.1007\/s12022-017-9498-z (2017).","journal-title":"Endocr. Pathol."},{"key":"94658_CR33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10014-018-0314-3","volume":"35","author":"N Inoshita","year":"2018","unstructured":"Inoshita, N. & Nishioka, H. The 2017 WHO classification of pituitary adenoma: Overview and comments. Brain Tumor Pathol. 35, 51\u201356. https:\/\/doi.org\/10.1007\/s10014-018-0314-3 (2018).","journal-title":"Brain Tumor Pathol."},{"key":"94658_CR34","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ecl.2014.10.008","volume":"44","author":"A Sav","year":"2015","unstructured":"Sav, A. et al. Invasive, atypical and aggressive pituitary adenomas and carcinomas. Endocrinol. Metab. Clin. N. Am. 44, 99\u2013104. https:\/\/doi.org\/10.1016\/j.ecl.2014.10.008 (2015).","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"94658_CR35","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-17-0796","volume":"178","author":"G Raverot","year":"2018","unstructured":"Raverot, G. et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur. J. Endocrinol. 178, G1\u2013G24. https:\/\/doi.org\/10.1530\/EJE-17-0796 (2018).","journal-title":"Eur. J. Endocrinol."},{"key":"94658_CR36","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1530\/EJE-17-0933","volume":"178","author":"A McCormack","year":"2018","unstructured":"McCormack, A. et al. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur. J. Endocrinol. 178, 265\u2013276. https:\/\/doi.org\/10.1530\/EJE-17-0933 (2018).","journal-title":"Eur. J. Endocrinol."},{"key":"94658_CR37","doi-asserted-by":"publisher","first-page":"E7","DOI":"10.3171\/foc.2004.16.4.8","volume":"16","author":"BT Ragel","year":"2004","unstructured":"Ragel, B. T. & Couldwell, W. T. Pituitary carcinoma: A review of the literature. Neurosurg. Focus 16, E7. https:\/\/doi.org\/10.3171\/foc.2004.16.4.8 (2004).","journal-title":"Neurosurg. Focus"},{"key":"94658_CR38","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s11102-018-0872-8","volume":"21","author":"F Yoo","year":"2018","unstructured":"Yoo, F., Kuan, E. C., Heaney, A. P., Bergsneider, M. & Wang, M. B. Corticotrophic pituitary carcinoma with cervical metastases: Case series and literature review. Pituitary 21, 290\u2013301. https:\/\/doi.org\/10.1007\/s11102-018-0872-8 (2018).","journal-title":"Pituitary"},{"key":"94658_CR39","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s11102-013-0537-6","volume":"17","author":"KS Park","year":"2014","unstructured":"Park, K. S., Hwang, J. H., Hwang, S. K., Kim, S. & Park, S. H. Pituitary carcinoma with fourth ventricle metastasis: treatment by excision and Gamma-knife radiosurgery. Pituitary 17, 514\u2013518. https:\/\/doi.org\/10.1007\/s11102-013-0537-6 (2014).","journal-title":"Pituitary"},{"key":"94658_CR40","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s11102-016-0721-6","volume":"19","author":"C Kamiya-Matsuoka","year":"2016","unstructured":"Kamiya-Matsuoka, C. et al. Radiotherapy with concurrent temozolomide for the management of extraneural metastases in pituitary carcinoma. Pituitary 19, 415\u2013421. https:\/\/doi.org\/10.1007\/s11102-016-0721-6 (2016).","journal-title":"Pituitary"},{"key":"94658_CR41","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1210\/jc.2014-4350","volume":"100","author":"D Bengtsson","year":"2015","unstructured":"Bengtsson, D. et al. Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. J. Clin. Endocrinol. Metab. 100, 1689\u20131698. https:\/\/doi.org\/10.1210\/jc.2014-4350 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"94658_CR42","doi-asserted-by":"publisher","first-page":"R559","DOI":"10.1530\/ERC-18-0228","volume":"25","author":"D Dworakowska","year":"2018","unstructured":"Dworakowska, D. & Grossman, A. B. Aggressive and malignant pituitary tumours: State-of-the-art. Endocr. Relat. Cancer 25, R559\u2013R575. https:\/\/doi.org\/10.1530\/ERC-18-0228 (2018).","journal-title":"Endocr. Relat. Cancer"},{"key":"94658_CR43","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1210\/jc.2011-2031","volume":"96","author":"AP Heaney","year":"2011","unstructured":"Heaney, A. P. Clinical review: Pituitary carcinoma: Difficult diagnosis and treatment. J. Clin. Endocrinol. Metab. 96, 3649\u20133660. https:\/\/doi.org\/10.1210\/jc.2011-2031 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"94658_CR44","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3389\/fendo.2020.00451","volume":"11","author":"AR Hong","year":"2020","unstructured":"Hong, A. R., Yoon, J. H., Kim, H. K. & Kang, H. C. Malignant prolactinoma with liver metastases masquerading as metastatic gastrointestinal stromal tumor: A case report and literature review. Front. Endocrinol. (Lausanne) 11, 451. https:\/\/doi.org\/10.3389\/fendo.2020.00451 (2020).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"94658_CR45","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3171\/ped.2004.101.2.0116","volume":"101","author":"C Lamas","year":"2004","unstructured":"Lamas, C. et al. Malignant prolactinoma with multiple bone and pulmonary metastases. Case report. J. Neurosurg. 101, 116\u2013121. https:\/\/doi.org\/10.3171\/ped.2004.101.2.0116 (2004).","journal-title":"J. Neurosurg."},{"key":"94658_CR46","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1530\/EJE-15-0967","volume":"174","author":"G Ntali","year":"2016","unstructured":"Ntali, G. et al. Mortality in patients with non-functioning pituitary adenoma is increased: Systematic analysis of 546 cases with long follow-up. Eur. J. Endocrinol. 174, 137\u2013145. https:\/\/doi.org\/10.1530\/EJE-15-0967 (2016).","journal-title":"Eur. J. Endocrinol."},{"key":"94658_CR47","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ecl.2018.02.005","volume":"47","author":"P Javanmard","year":"2018","unstructured":"Javanmard, P., Duan, D. & Geer, E. B. Mortality in patients with endogenous Cushing\u2019s syndrome. Endocrinol. Metab. Clin. N. Am. 47, 313\u2013333. https:\/\/doi.org\/10.1016\/j.ecl.2018.02.005 (2018).","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"94658_CR48","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.radonc.2012.04.024","volume":"104","author":"MG Sattler","year":"2012","unstructured":"Sattler, M. G. et al. The incidence of second tumours and mortality in pituitary adenoma patients treated with postoperative radiotherapy versus surgery alone. Radiother. Oncol. 104, 125\u2013130. https:\/\/doi.org\/10.1016\/j.radonc.2012.04.024 (2012).","journal-title":"Radiother. Oncol."},{"key":"94658_CR49","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/cen.13141","volume":"85","author":"MW O'Reilly","year":"2016","unstructured":"O\u2019Reilly, M. W. et al. ACTH and gonadotropin deficiencies predict mortality in patients treated for nonfunctioning pituitary adenoma: Long-term follow-up of 519 patients in two large European centres. Clin. Endocrinol. (Oxf.) 85, 748\u2013756. https:\/\/doi.org\/10.1111\/cen.13141 (2016).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"94658_CR50","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1365-2265.2006.02545.x","volume":"65","author":"J Lindholm","year":"2006","unstructured":"Lindholm, J. et al. Hypopituitarism and mortality in pituitary adenoma. Clin. Endocrinol. (Oxf.) 65, 51\u201358. https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02545.x (2006).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"94658_CR51","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1530\/EJE-17-0340","volume":"177","author":"C Hammarstrand","year":"2017","unstructured":"Hammarstrand, C. et al. Higher glucocorticoid replacement doses are associated with increased mortality in patients with pituitary adenoma. Eur. J. Endocrinol. 177, 251\u2013256. https:\/\/doi.org\/10.1530\/EJE-17-0340 (2017).","journal-title":"Eur. J. Endocrinol."},{"key":"94658_CR52","doi-asserted-by":"publisher","first-page":"E1938","DOI":"10.1210\/jc.2012-2432","volume":"97","author":"T Zueger","year":"2012","unstructured":"Zueger, T. et al. Glucocorticoid replacement and mortality in patients with nonfunctioning pituitary adenoma. J. Clin. Endocrinol. Metab. 97, E1938-1942. https:\/\/doi.org\/10.1210\/jc.2012-2432 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"94658_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/EJE-18-0166","volume":"180","author":"MR Postma","year":"2019","unstructured":"Postma, M. R. et al. Postoperative use of somatostatin analogs and mortality in patients with acromegaly. Eur. J. Endocrinol. 180, 1\u20139. https:\/\/doi.org\/10.1530\/EJE-18-0166 (2019).","journal-title":"Eur. J. Endocrinol."},{"key":"94658_CR54","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3171\/JNS\/2008\/108\/4\/0736","volume":"108","author":"EF Chang","year":"2008","unstructured":"Chang, E. F. et al. Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. J. Neurosurg. 108, 736\u2013745. https:\/\/doi.org\/10.3171\/JNS\/2008\/108\/4\/0736 (2008).","journal-title":"J. Neurosurg."},{"key":"94658_CR55","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11102-007-0018-x","volume":"10","author":"EH Nielsen","year":"2007","unstructured":"Nielsen, E. H. et al. Nonfunctioning pituitary adenoma: Incidence, causes of death and quality of life in relation to pituitary function. Pituitary 10, 67\u201373. https:\/\/doi.org\/10.1007\/s11102-007-0018-x (2007).","journal-title":"Pituitary"},{"key":"94658_CR56","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.1210\/jc.2004-1381","volume":"90","author":"R Kauppinen-Makelin","year":"2005","unstructured":"Kauppinen-Makelin, R. et al. A nationwide survey of mortality in acromegaly. J. Clin. Endocrinol. Metab. 90, 4081\u20134086. https:\/\/doi.org\/10.1210\/jc.2004-1381 (2005).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"94658_CR57","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1210\/jc.2012-2893","volume":"98","author":"JK Lambert","year":"2013","unstructured":"Lambert, J. K. et al. Predictors of mortality and long-term outcomes in treated Cushing\u2019s disease: A study of 346 patients. J. Clin. Endocrinol. Metab. 98, 1022\u20131030. https:\/\/doi.org\/10.1210\/jc.2012-2893 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"94658_CR58","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1210\/jc.2015-1475","volume":"100","author":"DS Olsson","year":"2015","unstructured":"Olsson, D. S. et al. Excess mortality in women and young adults with nonfunctioning pituitary adenoma: A Swedish nationwide study. J. Clin. Endocrinol. Metab. 100, 2651\u20132658. https:\/\/doi.org\/10.1210\/jc.2015-1475 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"94658_CR59","doi-asserted-by":"publisher","first-page":"e183317","DOI":"10.1001\/jamapediatrics.2018.3317","volume":"172","author":"SQ Khan","year":"2018","unstructured":"Khan, S. Q. et al. Infant and youth mortality trends by race\/ethnicity and cause of death in the United States. JAMA Pediatr. 172, e183317. https:\/\/doi.org\/10.1001\/jamapediatrics.2018.3317 (2018).","journal-title":"JAMA Pediatr."},{"key":"94658_CR60","doi-asserted-by":"publisher","first-page":"e0154535","DOI":"10.1371\/journal.pone.0154535","volume":"11","author":"NA Mode","year":"2016","unstructured":"Mode, N. A., Evans, M. K. & Zonderman, A. B. Race, Neighborhood economic status, income inequality and mortality. PLoS ONE 11, e0154535. https:\/\/doi.org\/10.1371\/journal.pone.0154535 (2016).","journal-title":"PLoS ONE"},{"key":"94658_CR61","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2105\/AJPH.2018.304787","volume":"109","author":"AG Cosby","year":"2019","unstructured":"Cosby, A. G. et al. Growth and persistence of place-based mortality in the United States: The rural mortality penalty. Am. J. Public Health 109, 155\u2013162. https:\/\/doi.org\/10.2105\/AJPH.2018.304787 (2019).","journal-title":"Am. J. Public Health"},{"key":"94658_CR62","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s10143-014-0525-y","volume":"37","author":"TM Hansen","year":"2014","unstructured":"Hansen, T. M. et al. Invasive adenoma and pituitary carcinoma: A SEER database analysis. Neurosurg. Rev. 37, 279\u2013285. https:\/\/doi.org\/10.1007\/s10143-014-0525-y (2014).","journal-title":"Neurosurg. Rev."},{"key":"94658_CR63","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s12020-019-01996-9","volume":"65","author":"G Aharon-Hananel","year":"2019","unstructured":"Aharon-Hananel, G., Percik, R., Badarna, M., Uri, I. & Tirosh, A. Lower all-cause mortality rates in patients harboring pituitary carcinoma following the introduction of temozolomide. Endocrine 65, 393\u2013398. https:\/\/doi.org\/10.1007\/s12020-019-01996-9 (2019).","journal-title":"Endocrine"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94658-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94658-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94658-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T11:45:42Z","timestamp":1670067942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94658-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,26]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["94658"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-94658-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,26]]},"assertion":[{"value":"3 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15155"}}